Laboratory of Pharmacology of Thrombosis and Atherosclerosis
The research activity is organized in two main areas: the study of cellular and molecular mechanisms involved in the development of cardio- and cerebro-vascular diseases and the evaluation of innovative pharmacological approaches for their prevention and treatment.
1. In the first line, the research is aimed at characterizing the mechanisms underlying the development and progression of cerebral and cardiac ischemia and the pathological conditions that occur after ischemic insult and that lead to maladaptive remodeling of tissues. Particular attention is paid to the involvement of inflammatory processes and mitochondrial damage and their pharmacological modulation.
2. In the second line, the research is more closely related to atherotrombotic- based cardiovascular diseases and focuses on a) the study of cellular and molecular mechanisms involved in thrombotic complications related to coronary syndrome, both "primary" and "secondary" to interventional cardiology and cardiac surgery procedures; b) the identification of mechanisms responsible for resistance to antiplatelet drugs and biomarkers able to improve the thrombotic risk stratification with the aim to taylor a personalized pharmacological treatment. The close cooperation with the Centro Cardiologico Monzino IRCCS gives this line of research a strong translational connotation.
The laboratory has expertise in the development and management of experimental models of cerebral, cardiac and renal pathologies, in particular those based on inflammation or induced by ischemic or hypertensive processes.
In addition to the use of cellular and molecular biology techniques, the study of these pathologies also makes use of non-invasive imaging techniques, such as nuclear magnetic resonance imaging (Bruker Avance II 4.7 T scanner) and high-resolution ultrasound (VisualSonics Vevo2100), approaches that allow the evolution of the pathology and the effect of pharmacological treatment to be followed over time.
Platelet activation, as the central mechanism in thrombotic complications of cardiovascular disease, and the response to pharmacological treatment are studied using a wide range of instruments that assess platelet function and global hemostasis both ex vivo (aggregometer, thromboelastometer, thrombinoscope, PFA-100, VerifyNow) and in flow conditions (Venaflux). The cytofluorimetry, with the latest generation instruments, is widely exploited to investigate the aspects of platelet heterogeneity and the study of circulating microvesicles. Finally, -omic approaches are used for the study of transcriptome, proteome and platelet metabolome.
The laboratory is the owner of numerous funds from national and international institutions (Cariplo 2015, Aspire 2016, PRIN 2017, Cariplo 2018) that allow to collaborate with numerous research groups.
Since February 2018, Prof. ssa Camera has been Chaiperson of the Platelet Physiology Committee in the SSC-ISTH Scientific and Standardization Committee and collaborates in the drafting of guidelines issued by this scientific society.
PCSK9 as a positive modulator of platelet activation
Camera M, Rossetti L, Barbieri SS, Zanotti I, Canciani B, Trabattoni D, Ruscica M, Tremoli E, Ferri N.
J Am Coll Cardiol 2018; 71: 952-954
Impact of angiotensin-converting enzyme inhibition on platelet Tissue Factor expression in stroke-prone rats
Brambilla M, Gelosa P, Rossetti L, Castiglioni L, Zara C, Canzano P, Tremoli E, Sironi L Camera M.
J Hypertens 2018; 36:1360-1371
PCSK9 involvement in aortic valve calcification
Poggio P, Songia P, Cavallotti L, Barbieri SS, Zanotti I, Arsenault BJ, Valerio V, Ferri N, Capoulade R, Camera M.
J Am Coll Cardiol 2018; 72:3225-3227
Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection
L Castiglioni, A Pignieri, M Fiaschè, M Giudici, M Crestani, N Mitro, M Abbate, C Zoja, D Rottoli, C Foray, F Fiordaliso, U Guerrini, E Tremoli, L Sironi, P Gelosa
J Hypertens 2018; 36:1129-1146
Improvement of fiber connectivity and functional recovery after stroke by montelukast, an available and safe anti-asthmatic drug
Gelosa P, Bonfanti E, Castiglioni L, Delgado-Garcia JM, Gruart A, Fontana L,Gotti M, Tremoli E, Lecca D, Fumagalli M, Cimino M, Aigner L, Abbracchio MP, Sironi L.
Pharmacol Res 2019; 142:223-236